Latest Healthcare News

Argent BioPharma has finalized the acquisition of CannPal Animal Therapeutics, securing a Phase 3 veterinary epilepsy asset with near-term commercial prospects and an option to acquire the Neuvis® drug delivery platform, enhancing its neurological portfolio and U.S. market ambitions.

Monash IVF has received a revised $0.90 per share acquisition proposal from a consortium led by Genesis Capital and WHSP Holdings, upping the ante from a previous $0.80 offer. The deal hinges on exclusivity and unanimous board support, with no guarantee of completion.

Talius Group has inked a Master Services Agreement with Adventist Retirement Plus to roll out its Nurse Call and Sleep Systems across two Queensland villages, setting the stage for wider expansion and recurring revenue growth.

Telix Pharmaceuticals and Regeneron have entered a strategic collaboration to co-develop next-generation radiopharmaceutical therapies, with Telix receiving a $40 million upfront payment and potential milestones exceeding $2 billion.

Little Green Pharma Ltd (ASX:LGP) has secured overwhelming shareholder approval from Cannatrek Ltd for its proposed acquisition scheme, advancing the transaction toward Federal Court approval and implementation by early May 2026.

Lumos Diagnostics Holdings Limited (ASX: LDX) has opened a Share Purchase Plan (SPP) offering eligible shareholders the chance to invest up to A$30,000 at A$0.225 per share, accompanied by free options. The SPP aims to raise up to A$2 million and closes on 24 April 2026.

Telix Pharmaceuticals has announced FDA acceptance of its resubmitted NDA for TLX101-Px (Pixclara®), a PET imaging agent for glioma, setting a PDUFA goal date of September 11, 2026. The agent addresses a significant unmet need in distinguishing recurrent glioma from treatment effects.

Pacific Edge reported a 2.7% increase in test volumes for Q4 2026 despite operational challenges, supported by growing momentum toward Medicare coverage and expanded commercial payer adoption in the US and Asia Pacific.

Careteq Limited has finalised the sale of its Embedded Health Solutions subsidiary for approximately $5 million, repaid related vendor loans, and plans to concentrate on growing its HMR Referrals platform amid ongoing regulatory and compliance considerations.

EBR Systems has reported a significant increase in commercial implantations of its WiSE System in Q1 2026, more than doubling case volumes from the previous quarter and projecting preliminary revenue between US$2.25 million and US$2.36 million.

Mesoblast Limited (ASX:MSB, Nasdaq:MESO) has received FDA Investigational New Drug clearance to initiate a pivotal clinical trial of its cell therapy Ryoncil in children with Duchenne Muscular Dystrophy, aiming to address inflammation-driven disease progression.

Neuren Pharmaceuticals’ partner Acadia Pharmaceuticals has broadened availability of DAYBUE STIX, a new FDA-approved powder formulation of trofinetide for Rett syndrome, in the US. Early caregiver feedback and expert consensus highlight its potential role in personalised patient care.